Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make representation as to its accuracy or completeness and expressly disclaim any liabi whatsoever for any loss howsoever arising from or in reliance upon the whole or part of the contents of this announcement.

SHENZHEN HEPALINK PHARMACEUTICA L GROUP CO., LT D. (深圳市海普瑞藥業集團股份有限公司) (A joint stockcompanyincorporated in the People's Republic of China with limited liability)

(Stockcode:9989)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

- 	Company	Board) Hepalink)	Gro Reportin	oup, we, g Perio¢l	our us)
FINA	NCIAL HIGHLIGH	HTS			
st. St.					
			For the six 2024 RMB'000	Ø	ended June 30, % O
4			2,828,657	2	4
1 m			999,274	5 -	4
1 m			35.3%	3	
y.com			663,684	ß	\$
.1			2,202,718	1	2
-د			34.3%	3	
• \$			1,294,842	(

FINANCIAL HIGHLIGHTS

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS For the six months ended June 30, 2024

	Notes	Six months en 2024 RMB'000 (unaudited)	Ø RMB'000
REVENUE	4	2,828,657 (1,829,383)	2 (
Gross profit		999,274	5 -
er F Zu er	5	406,625 (191,911) (279,610)	Ø ((
1 5 - 5 -	6	11,446 (15,906) (84,504) (77,765)	(((

2

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 30, 2024

	Six months ended June 30,		
	2024 Q		
	RMB'000	RMB'000	
	(unaudited)	(
PROFIT FOR THE PERIOD	662,836	2	

OTHER COMPREHENSIVE INCOME

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, 2024

I	Notes	June 30, 100 2024 RMB'000 (unaudited)	l.	می م 000'
NON-CURRENT ASSETS				
5		2,648,093	2	
÷		203,977	Ø	
٣		2,336,835	2	
		366,955	₿-	
■ ∖ź		508,835	1	
T 🖌		606,221	ø	
T and the second s		817,111	1	
		259,425	ß	
6		117,400	Ø	
	_	107,022		\boxtimes
Total non-current assets	_	7,971,874	8	
CURRENT ASSETS				
st. and the second s		6,022,241	6	
و	11	1,314,094	1	
ج س الللہ ،		11,015	Ø	
, 100 ,		648,765	\$	
		45,653	\$	
T Jan		332,872	4	
, Kan		548	7	\boxtimes
₩ 1		2,280		0
		21,450	8	-
	_	2,202,718	1	
Total current assets	-	10,601,636	Ø	
Total assets	-	18,573,510	9 -	


INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Continued)

June 30, 2024

	Notes	June 30, 1 2024 RMB'000 (unaudited)	0 RMB'000 (
CURRENT LIABILITIES			
s \$**	12	378,167	0 8
		431,825	0 g -
\$ \$		367,641	B
£		2,992,776	3
1		186,129	\$
E Contraction of the second se		89,937 33,434	4 3
\neg	-		Ŷ
Total current liabilities	-	4,479,909	<u></u> ,
NON-CURRENT LIABILITIES			
⊾ ∖ź		1,496,572	1
		28,254	ß
Ç.		242,464	2
		32,996 10,242	3 0
ж.,	-	73,650	¢-
Total non-current liabilities	-	1,884,178	2
NET CURRENT ASSETS	-	6,121,727	5
TOTAL ASSETS LESS CURRENT			
LIABILITIES	-	14,093,601	4
Net assets		12,209,423	1
SHAREHOLDER EQUITY			
6		1,467,296	1
\$ ^m	-	10,667,729	0
< Comparison of the second sec		12,135,025	1
	-	74,398	3
Total shareholder equity		12,209,423	1


MANAGEMENT DISCUSSION AND ANALYSIS

Overview



Industry Review

1 -, C 1.... ~* 1.u. E , 5 . T "**M 9**-



ų, (**I**) Sales Heparin Industrial Chain Business đ Ì) 1 **^**| *****| ç ť , , Ø







CDMO Business

y,,**

,9



Innovative Drugs and Innovative Business



Oregovomab

ч 	7	
1	۴	
я́г.		
(
laa Raa	۳	

AR-301 (Salvecin)



,

H1710

1 1....,

Outlook


,		
	ť'	
1.u., 1.u.,	i. K	
¢.		
า โณ	Å	

-
- **%**



,

,



Financial Review Revenue

	2024 sales amount% o RMB 000	2024 of revenue	0 M	Ø %	Year-on-year increase/ decrease (%)
	(unaudited)		(
ſ	2,245,298	79.4%	2	8	(
÷ (1,453,516	51.4%	1	5	(
1	747,599	26.4%	6 -	3	7
ým (44,183	1.6%	4	11	0
M	560,378	19.8%	5 -	4	4
ým (22,981	0.8%	2	0	7
Total	2,828,657	100%		Ø	4

For the six months ended June 30,

Notes:


(5

(5°





Finance Costs



¢,



Earnings per Share

¢

\$




Liquidity and Financial Resources Treasury Policies



سم معر ع

Capital Structure



Pledge of Assets

. 1 1

Contingent Liabilities

. Ì

Asset-liability Ratio

Interest Rate Risk

ی چ پ پ

Indebtedness

	As at June 30, 1 2024 RMB'000 (unaudited)	0 RMB'000 (
چ ج ۲	4,489,348 107,084	5 B
้า	4,596,432	5
,	(2,280)	(
•	4,594,152	5

	As at June 30, 1 2024 2 RMB'000 RMB'000 (unaudited) (
1 	2,992,776 3 823,328 7 124,652 6 548,592 5
ไ	4,489,348 5
, 1, 1 	


ø 3

,


NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

For the six months ended June 30, 2024

1. Corporate Information







- 3. Operating Segment Information

ťan,	,	ر ۲ RMB'000	RMB'000	MM RMB'000	م ۳ RMB'000	ן RMB'000
tu 1 Fu	, ,	1 1 2	• 1	5 4 5	6 J	2 2 5
Î щ - ⁻ 1щ	3					(2
fu, 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, , , ,	Ø	3	1	2	1 (0 ((((((
¥.						ø

É

Geographical information

(a) Revenue from external customers

	For the six months	ended June 30,
	2024	Ø
	RMB'000	RMB'000
	(unaudited)	(
¥	6,678	4
	580,353	5
2	1,390,708	1
Nation 1	187,627	₽ -
l.	663,291	Ø
	2,828,657	2

(b) Non-current assets

.

	As at June 30, 1 2024 RMB'000 (unaudited)	0 RMB'000 (
	2,825,277 3,305,483	2 3
) V	157,000 1,357	ф Ф
1	6,289,117	6

Information about major customers

đ

, 1

Ť

1. T

ŕ

I

4. Revenue

Revenue from contracts with customers

(🔨

For the six months ended June 30, 2024 (unaudited)

Segment	Finished dose pharmaceutical products RMB'000	API RMB'000	CDMO RMB'000	Others RMB'000	Total RMB'000	
Type of goods or services	1,453,516	747,599	560,378	44,183 22,981	2,245,298 560,378 22,981	
) v	1,453,516	747,599	560,378	67,164 <td>ang (en-GB)/MCID 13</td> <td>¢ 388 >>BDC,</td>	ang (en-GB)/MCID 13	¢ 388 >>BDC,

łu, ,	ر ۳ RMB'000	RMB′000	শ্ব≣ RMB′000	√ RMB′000	ן RMB'000
Type of goods or services	1,547,336	698,062	395,381	44,128 21,339	2,289,526 395,381 21,339
ן ~	1,547,336	698,062	395,381	65,467	2,706,246
Timing of revenue recognition	1,547,336	698,062	133,593 261,788	44,128 6,682 14,657	2,289,526 140,275 276,445
1 ~	1,547,336	698,062	395,381	65,467	2,706,246

ť

í

ć

¢

ć

¢

8

6		
	For the six months	s ended June 30,
	2024	Ø
	RMB'000	RMB'000
	(unaudited)	(
r		
Ĩ	22,859	3
	425,851	₽-
	448,710	Ŗ

(

<u>مرک</u> ۲۴ چ

, T

¥

I Ť

` ~

Sale of products

,

1

*

CDMO services

£	FFS)
v er	
Ť	

As at . June 30, 1_س 2024 മ

•

June 30, 2024 RMB'000 (unaudited)	1 m	ب ۵ RMB'000
355,242		2

5. Other Income and Gains

	For the six months ended June 30 2024 Ø	
	RMB'000 (unaudited)	RMB'000 (
Other income		
	18,596	<u>3</u>
staa, > ⊠	1,281	1
 X	3,003	¢ Ø
4	207,876	
	230,756	ß
Other gains		
Other gains £	(12,134)	ß
e C	1,361	8
E 6 C	(96,283)	8
	8,607	(
(1 ₁₁₁ , ,	(583)	ß
- 10. 	272,018	7
6	2,883	8
	175,869	Ø
	406,625	Ø
*		
,		
ί μ, , 1		
* ,		
es La companya de la comp		
≂		
÷		

%

÷.

۰ بر

ß

6. Finance Costs

.

	For the six month	s ended June 30,
	2024	Ø
	RMB'000	RMB'000
	(unaudited)	(
¢		
	71,970	₽-
5	6,796	2
₩ ₂ ,	776	2
6	4,962	Ø
	84,504	ß

7. Profit before Tax

,

,

مرجي مرجع

اللہ میں مسلح

Lui,

¢

K, /

(

£

*

í.

ř

...

1

	For the six months	
	2024	Ø
	RMB'000	RMB'000
	(unaudited)	(
	1,443,136	1
	386,247	9 -
	128,038	ß
	18,686	₽-
S. Martin C.	27,651	7
	81,041	5 -
	2,698	4
, f		
	229,924	3
e**	52,627	"-
I	(18,596)	(
	84,504	ß
	12,134	(
	(1,361)	(
	(8,607)	2
	96,283	(
, ,	583	(
\$ 	(272,018)	(
	(11,446)	<u>4</u>
	(13,934)	(
L.		

3

8. Income Tax Expense

,


	For the six months ended June 3		
	2024	Ø	
	RMB'000	RMB'000	
	(unaudited)	(
¢r.			
	4,776	3	
· ···	58,720	(
4 Martin Carlo Car	4,525	4	
	(5,041)	8	
	62,980	4	
(
	50,552	9 -	
198.	(2,020)	3	
	(6,699)	(
	41,833	3	
้า	104,813	\$	

9. Dividends

,

For the six months ended June 30, 2024 Ø RMB'000 RMB'000 (unaudited) (

10. Earnings per Share Attributable to Ordinary Equity Holders of the Parent



	RMB'000 (unaudited)	RMB'000 (
¢ I T	1,342,426 2,429 (30,761)	1 3 (
	1,314,094	1

*		
	As at	
	June 30,	În, C
	2024	۵ آ
	RMB'000	RMB'000
	(unaudited)	(
¥	1,009,476	1
	304,769	2-
	7,400	Ø
	23,210	2
	1,344,855	1
K γ	30,761	Ø
	1,314,094	1

r T

,

				As at	*
				June 30,	Ĩu,
				2024	Ø
				RMB'000	RMB'000
				(unaudited)	(
•				40,039	4
1	Í.	,		(8,491)	2
1 E	0.000				(
*			_	(787)	ļ
			_	30,761	Ø
			-		

12. Account Payables


	As at June 30, 2024 RMB'000 (unaudited)	1 u 0 RMB'000 (
C	378,167	Ø
· 		
	As at June 30, 2024 RMB'000 (unaudited)	1 u. Ø RMB'000 (
· · ·	373,914 3,276 476 501	9- 3 4 1
	378,167	Ø

13. Share Capital

,

	As at June 30, 2024 RMB'000 (unaudited)	نمر ور ۲۵ RMB'000 (
б. 5	1,467,296	1

Use of Proceeds from the H Share Listing of the Company



- •
- y Car
- . ⊊‴

,		

~

1

Business objectives	as at the date of the Announcement	Unutilized Net Proceeds e as at December 31, 2023 (RMB million)	six months ended June 30, 2024	utilization of Net Proceeds as of June 30, 2024	as at June 30, 2024		
(100, 🐔	X		×	ļ	×)	
(: ; ; ; ,	8	8	3	б	2	2	
(zi s s	Ø	2	2	3	4	3	
(, _{)M,} ,	0	8	×	9 -	0	4	
(0	9	0	1	⊠	5	2 6 1 1
ì	<u> </u>	0	2	3	<u>}</u>		


,

.

- *
- **W** 1

```
, (-
, -
, -
           ۶.
The second
Significant Investments
y an
Purchase, Sale or Redemption of Listed Securities
15
           ;
1....
•
Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures
Í.
4
Events after the Reporting Period
,
•
Employee and Remuneration Policy
```

Compliance with the Model Code for Securities Transactions by Directors of Listed Issuers



Appreciation



Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Li Li Chairman

* *

As at the date of this announcement, the executive directors of the Company are N Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.

This announcement contains forward-looking statements relating to the business out estimates of financial performance, forecast business plans and growth strategies of Group. These forward-looking statements are based on information currently available to the Group and are stated herein on the basis of the outlook at the time of announcement. They are based on certain expectations, assumptions and premises, so of which are subjective or beyond control of the Group. These forward- looking statements may prove to be incorrect and may not be realised in the future. Under these forward-looking statements are a large number of risks and uncertainties. In I of the risks and uncertainties, the inclusion of forward-looking statements in announcement should not be regarded as representations by the Board or the Comp